Daiwa Securities Group’s Coherus Oncology CHRS Stock Holding History

Daiwa Securities Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-262	Closed	–	–	1291
2024 Q3	$0	Hold	262	–	–	﹤0.01%	1287
2024 Q2	$0	Hold	262	–	–	﹤0.01%	1326
2024 Q1	$1K	Hold	262	–	–	﹤0.01%	1291
2023 Q4	$1K	Hold	262	–	–	﹤0.01%	1292
2023 Q3	$1K	Hold	262	–	–	﹤0.01%	1242
2023 Q2	$1K	Hold	262	–	–	﹤0.01%	1263
2023 Q1	$2K	Hold	262	–	–	﹤0.01%	1208
2022 Q4	$2K	Hold	262	–	–	﹤0.01%	1216
2022 Q3	$3K	Hold	262	–	–	﹤0.01%	1189
2022 Q2	$2K	Hold	262	–	–	﹤0.01%	1228
2022 Q1	$3K	Hold	262	–	–	﹤0.01%	1213
2021 Q4	$4K	Hold	262	–	–	﹤0.01%	1216
2021 Q3	$4K	Buy	262 +127	+94%	+$1.86K	﹤0.01%	1191
2021 Q2	$2K	Hold	135	–	–	﹤0.01%	1136
2021 Q1	$2K	Hold	135	–	–	﹤0.01%	1138
2020 Q4	$2K	Sell	135 -261	-66%	-$4.65K	﹤0.01%	1117
2020 Q3	$7K	Hold	396	–	–	﹤0.01%	1065
2020 Q2	$6K	Hold	396	–	–	﹤0.01%	1096
2020 Q1	$6K	Hold	396	–	–	﹤0.01%	1089
2019 Q4	$7K	Sell	396 -44	-10%	-$811	﹤0.01%	1085
2019 Q3	$9K	Hold	440	–	–	﹤0.01%	1037
2019 Q2	$10K	Hold	440	–	–	﹤0.01%	1056
2019 Q1	$6K	Buy	440 +120	+38%	+$1.6K	﹤0.01%	1066
2018 Q4	$3K	Hold	320	–	–	﹤0.01%	1088
2018 Q3	$5K	Hold	320	–	–	﹤0.01%	1081
2018 Q2	$4K	Hold	320	–	–	﹤0.01%	1107
2018 Q1	$4K	Buy	+320	New	+$3.5K	﹤0.01%	1087

Other funds holding CHRS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Daiwa Securities Group's CHRS Position: Q4 2024 in Review

Daiwa Securities Group sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 262 shares.

Daiwa Securities Group first reported a position in CHRS in Q1 2018 and held it in 27 quarters. The position peaked at $10K in Q2 2019. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

Daiwa Securities Group reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
Daiwa Securities Group sold 262 Coherus Oncology shares in Q4 2024.
Daiwa Securities Group first reported a position in Coherus Oncology in Q1 2018 and held it in 27 quarters.
Daiwa Securities Group's Coherus Oncology position peaked at $10K in Q2 2019.
124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.